NEW YORK (GenomeWeb) – Natera reported after the market on Tuesday that its first quarter 2017 revenues declined 24 percent over the first quarter 2016.

The San Carlos, California-based molecular diagnostics firm recognized $46.9 million in Q1 revenues, down from $61.9 million in Q1 2016. It beat analysts' average estimate of $42.8 million.